NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) — Law Firm Edelson Lechtzin LLP Reminds Investors to Purchase Enochian Biosciences Inc. (“Enochian” or the “Company”) NOV Common Stock between February 16, 2018 and June 27, 2022, inclusive (the “Collection Period”) of the rapidly approaching deadline for filing a motion requesting the U.S. District Court for the Central District of California to name them as Lead Plaintiffs .

Investors who purchased Enochian during the class action period have until September 26, 2022 to select counsel and apply for appointment as lead plaintiff. The lead plaintiff acts as a representative for other group members in conducting the litigation. If you continue to own Enochian stock and would like to discuss your legal options, please contact Edelson Lechtzin LLP, toll-free at 1-844-696-7492 or email [email protected].

Background on the class action lawsuit against Enochian Biosciences securities

Enochian is a preclinical-stage biotechnology company purportedly discovering and developing pharmaceutical and biological products for the treatment of human immunodeficiency virus (“HIV”), hepatitis B virus (“HBV”), influenza and coronavirus infections, and cancer .

The complaint alleges that Enochian, a pre-clinical stage biotechnology company, has made false and misleading statements and material omissions through its officers regarding the company’s financial performance and future prospects. In particular, it is alleged that Enochian co-founder Gumrukcu was involved in a number of fraudulent misconduct, including not being a licensed physician and the scientific and technological basis of Enochian’s product pipeline allegedly invented by Gumrukcu was dubious at best. Thus, the defendants significantly overstated the commercial prospects for the Company’s product pipeline and threatened the integrity of the Company’s scientific findings, thereby rendering the Company’s public statements during the Class Period substantially false and misleading.